Xeris Biopharma Holdings (0A8E.L) Q4 2024 Earnings Report

Xeris Biopharma Holdings Inc reported revenue of $48 million in Q4 2024, a growth of 25.04% year-over-year, driven primarily by increased sales of its flagship product, Gvoke. However, the company faced significant operational challenges, evident in its gross profit margin of 78.15% which dropped 15.77% QoQ due to escalated operational costs and R&D expenses amounting to $5.76 million. \nManagement emphasizes a strategic shift to optimize the portfolio and address underlying cost issues, hinting at a cautious yet ambitious approach moving forward. Despite operational losses with a net income of -$15 million, management is optimistic about the growth potential stemming from continued product positioning and upcoming product launches in the pipeline.